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Abstract
Background: Enterococcal meningitis is an uncommon disease usually caused by Enterococcus
faecalis and Enterococcus faecium and is associated with a high mortality rate. Enterococcus
casseliflavus has been implicated in a wide variety of infections in humans, but never in meningitis.
Case presentation: A 77-year-old Italian female presented for evaluation of fever, stupor,
diarrhea and vomiting of 3 days duration. There was no history of head injury nor of previous
surgical procedures. She had been suffering from rheumatoid arthritis for 30 years, for which she
was being treated with steroids and methotrexate. On admission, she was febrile, alert but not
oriented to time and place. Her neck was stiff, and she had a positive Kernig's sign. The patient's
cerebrospinal fluid was opalescent with a glucose concentration of 14 mg/dl, a protein level of 472
mg/dl, and a white cell count of 200/µL with 95% polymorphonuclear leukocytes and 5%
lymphocytes. Gram staining of CSF revealed no organisms, culture yielded E. casseliflavus. The
patient was successfully treated with meropenem and ampicillin-sulbactam.
Conclusions: E. casseliflavus can be inserted among the etiologic agents of meningitis. Awareness
of infection of central nervous system with Enterococcus species that possess an intrinsic
vancomycin resistance should be increased.
Background
Enterococcal meningitis is an uncommon disease
accounting for only 0.3% to 4% of cases of bacterial men-
ingitis which is nevertheless associated with a high mor-
tality rate. It has been described most frequently in
patients with neurosurgical conditions (i.e. head trauma,
shunt devices, or cerebrospinal fluid leakage), although it
can also occur as a "spontaneous" infection complicating
remote enterococcal infections such as endocarditis or
pyelonephritis [1].
Enterococcus faecalis and Enterococcus faecium are the two
species most frequently isolated during the course of men-
ingitis (76%–90% and 9–22% respectively). Enterococcus
casseliflavus, first considered as a subspecies of E. faecium,
is a motile enterococcus that produces a yellow pigment
in agar and often has a VanC phenotype determining an
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implicated in a wide variety of infections in humans, espe-
cially immunocompromised hosts, but to the best of our
knowledge it has never been associated to meningitis [2-
5].
We describe here a case of enterococcal meningitis caused
by E. casseliflavus that was believed to originate from the
gut in an old patient with bowel erosions.
Case presentation
A 77-year-old Italian female presented for evaluation of
fever, stupor, diarrhea and vomiting of 3 days duration.
She had no urinary symptoms. There was no history of
head injury nor of previous surgical procedures. She had
been suffering from rheumatoid arthritis for 30 years, for
which she was being treated with steroids and methotrex-
ate; other medical problems were insulin-dependent dia-
betes and moderate renal failure.
On admission, she was febrile (temperature, 38.0°C),
alert but not oriented to time and place. Her neck was stiff,
and she had a positive Kernig's sign. A CT brain scan
showed an increase in subarachnoid space and in the vol-
ume of the ventricular system.
Laboratory examinations revealed a white blood cell
count of 15,100/µL with 70% neutrophils and 23% lym-
phocytes. Results of urinalysis were unremarkable. Cul-
tures of blood and urine were drawn and subsequently
resulted negative.
The patient's cerebrospinal fluid (CSF) was opalescent
with a glucose concentration of 14 mg/dl, a protein level
of 472 mg/dl, and a white cell count of 200/µL with 95%
polymorphonuclear leukocytes and 5% lymphocytes.
Gram staining of CSF revealed no organisms. Pending the
culture results the patient was empirically treated with
intravenous meropenem, cotrimoxazole, acyclovir and
dexamethasone.
Culture of CSF yielded E. casseliflavus that was identified
using the Vitek-2 system (bioMérieux-Vitek) on the basis
of 6.5% NaCl tolerance, bile-esculin hydrolysis, and
growth rate at 45°C, arginine hydrolysis, methyl-a-D-glu-
copyranoside testing, and acid production from ribose,
motility testing, and yellow pigmentation testing.
The isolate was sensitive to penicillin, ampicillin, ampicil-
lin-sulbactam, imipenem, teicoplanin, tetracyclines and
linezolid; it exhibited intermediate sensitivity to vanco-
mycin (MIC, ≥8 µg/mL), trimethoprim-sulfamethoxazole
(MIC, ≥10 µg/mL), levofloxacin (MIC, 4 µg/mL), nor-
floxacin (MIC, 8 µg/mL), ciprofloxacin (MIC, 2 µg/mL)
and quinupristin-dalfopristin (MIC, 2 µg/mL); it was
resistant to clindamycin (MIC, 4 µg/mL) and showed high
resistance to gentamicin, streptomycin and kanamycin
(MIC, ≥2000 µg/mL).
The patient became afebrile 48 hours after the beginning
of antibiotic therapy with rapid improvement of her men-
tal status and disappearance of meningeal signs (within
36 hours).
Once the organism was identified (4 days later), trimeth-
oprim-sulfamethoxazole and acyclovir were discontinued
and ampicillin-sulbactam (3 g every 6 hours) was added.
After 2 weeks of antibiotic therapy the patient was dis-
charged in good health with sterilization of the CSF cul-
ture. An echocardiogram revealed no vegetations whereas
a colonoscopy examination showed two ulcerative lesions
associated with two polyps, oedema and multiple punctu-
ate erosions.
Enterococcal infections of the central nervous system are
quite rare and according to a MEDLINE search of the Eng-
lish literature only three cases of CNS infection by a
motile Enterococcus identified as E. gallinarum have been
previously documented; they occurred in patients with
ventriculoperitoneal shunts for hydrocephalus [6,7]. E.
casseliflavus and E. gallinarum are responsible for 1–2% of
all enterococcal infections and are characterized by the
fact that they possess intrinsic low-level vancomycin
resistance [8]. The VanC-1 ligase is specific for E. galli-
narum, and the VanC-2/3 ligase is specific for E. casselifla-
vus [9]. Organisms with resistance to VanC remain
susceptible to teicoplanin. This naturally occurring vanco-
mycin resistance has not been shown to be transferable,
and the related genes are chromosomally encoded in the
members of these species [4,9,10].
Despite the intrinsic low-level vancomycin resistance
exhibited by E. casseliflavus it is important to remember
that most strains are susceptible to penicillin and ampicil-
lin. Combination therapy of ampicillin with an aminogly-
coside such as gentamicin or streptomycin is considered
the standard therapy of enterococcal meningitis due to
ampicillin-susceptible strains [1]. Meropenem is not
superior to ampicillin for therapy of enterococcal infec-
tions and most species of E. casseliflavus are beta-lactamase
negative. There was not therefore a clear indication for the
use of combination therapy with meropenem and a beta-
lactamase inhibitor in the case reported.
Our patient had gastrointestinal signs and symptoms, and
colonoscopy revealed multiple erosions, which probably
were the portal of entry of E. casseliflavus.
In fact, enterococcal meningitis may appear as a complica-
tion of diverse gastrointestinal diseases such as enterocol-Page 2 of 3
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itis, peritonitis, abdominal surgery, or bowel carcinoma. A
case of bowel erosions as the portal of entry of enterococ-
cal meningitis has been previously reported [11].
Several studies have demonstrated that E. gallinarum and
E. casseliflavus colonize the gastrointestinal tracts of both
hospitalized individuals and nonhospitalized healthy
ones [8,12,13]. Therapy with various antimicrobial
agents, including cephalosporins and vancomycin, may
play a role in increasing colonization with these organ-
isms. Edlund et al. reported a significant increase in the
emergence of E. gallinarum and E. casseliflavus in healthy
subjects who were administered oral vancomycin [14].
Our patient was not taking any antimicrobials before hos-
pital admission. E. gallinarum and E. casseliflavus/flavescens
are part of the normal stool flora of the general popula-
tion; this has perhaps impacted the ability of researchers
to detect specific risk factors [8].
Although our patient had significant underlying condi-
tions this case of meningitis was mild and had most of the
typical features of "spontaneous" enterococcal meningitis
(community-acquired infection, severe underlying dis-
eases, and immunodepression).
The clinical significance of the enterococci that are intrin-
sically resistant to vancomycin has not been fully estab-
lished yet. Infection with E. gallinarum and E. casseliflavus
has been associated with high mortality, but it is difficult
to attribute their mortality directly to infection or to the
underlying conditions of the patient.
Conclusions
This case is the first report of E. casseliflavus meningitis and
it is the fourth documented so far with a motile Enterococ-
cus species. Awareness of infection of central nervous sys-
tem with Enterococcus species that possess an intrinsic
vancomycin resistance should be increased.
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